By: ifood.tv

Eplerenone Versus Spironolactone as Treatment of Ascites Due to Liver Cirrhosis; a Study of Efficacy and Side Effects

Feb 28, 2013 No Comments by

This study compares Spironolactone, a non-selective aldosterone antagonist, with Eplerenone,
a selective aldosterone antagonist, regarding efficacy and hormonal side effects when
treating male cirrhotic patients with uncomplicated ascites over a 6 month period. The
investigators hypothesis is that Eplerenone is as effective as Spironolactone as treatment
of ascites with less side effects such as painful gynecomastia.

Clinical Trial Conditions: Ascites, Cirrhosis

Treatments in this Clinical Trial : Eplerenone

Clinical Trial Phase: Phase 2

Eligible Clinical Trial Participant Age : Between 18 years to 70 years

Can Healthy Volunteers Participate: No

Clinical Trial Lead Sponsor: Emma Nilsson

Detailed Clinical Trial Description: This study compares Spironolactone, a non-selective aldosterone antagonist, with Eplerenone,
a selective aldosterone antagonist, regarding efficacy and hormonal side effects when
treating male cirrhotic patients with uncomplicated ascites over a 6 month period. The
investigators hypothesis is that Eplerenone is as effective as Spironolactone as treatment
of ascites with less side effects such as painful gynecomastia.

The clinical trial information was obtained from http://clinicaltrials.gov/ct2/show/NCT01801228

New Clinical Trial

About the author

The author didnt add any Information to his profile yet
No Responses to “Eplerenone Versus Spironolactone as Treatment of Ascites Due to Liver Cirrhosis; a Study of Efficacy and Side Effects”

Leave a Reply

By: ifood.tv